Making the Omission of On-Site Monitoring the De Facto Standard and Reducing Clinical Trial Costs
First written in FY2022. 2 of 3 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The revised GCP ministerial ordinance based on ICH-E6(R3) is scheduled to take effect in April 2027, requiring correction of excessive quality management, or “overquality,” which has been an issue to date. By using its systems, the company will continue to reduce research and development costs for pharmaceutical companies and academic research institutions, including by eliminating and streamlining on-site monitoring, streamlining the subject recruitment process, improving clinical trial quality and shortening trial periods by preventing missing data.」
The company continues to pursue its policy of making the elimination of on-site monitoring the de facto standard and reducing clinical trial costs, linking it to preparations for the revised GCP ministerial ordinance scheduled for April 2027. - FY2023RestatedAnnual report
「We aim to establish the de facto standard for omitting on-site monitoring in clinical trials.」
The company continues to pursue its goals of establishing the de facto standard for omitting on-site monitoring and reducing clinical trial costs. - FY2022First statedAnnual report
「We aim to establish the de facto standard for omitting on-site monitoring in clinical trials.」
The company has, for the first time, explicitly stated its goal of establishing a widely adopted standard for a system that uses blockchain and other technologies to omit on-site monitoring.